Topic: CP55,940

In our previous studies, we developed a marker-based 3D motion capture system to evaluate step kinematics during behaviors such as climbing and novel environment exploration under various pharmacological treatments. In the present study, we aimed to test whether the step kinematics of mice is affected during treadmill running at different speeds and under various treatments. We used adult male C57BL/6 mice in a within-subject, randomized design. We recorded voluntary running behavior on a treadmill in mice treated with vehicle (1:1:18 ethanol, Kolliphor, saline), CP55,940 (0.3 mg/kg) or harmal

We have developed a marker-based 3D motion capture system for high-precision quantification of mouse locomotion. In our previous studies, we observed that a low dose of a synthetic agonist of cannabinoid CB1 and CB2 receptors, CP55,940 (0.3 mg/kg), causes a small reduction in general locomotion during open-field exploration, but does not inhibit general locomotion during vertical climbing. However, we observed that it induces significant changes in step kinematics during both tasks, which were more pronounced during climbing.We used adult male C57BL/6 mice in a within-subject, randomized desig